Glactone Pharma has developed a pipeline of novel STAT3 (signal transducer and activator of transcription 3) inhibitors for the use in immuno-oncology and for the treatment of drug resistant cancers (including castration resistant prostate cancer). STAT3 is directly involved in tumor mediated immune suppression and in mechanisms leading to resistance to targeted therapies, making it an ideal target in combination treatments.
Our objective is to take a candidate drug into clinical trials. Thereafter the intention is to divest the company to a larger company that can secure the further development, registration and commercialization of this novel treatment, making it available to patients, and to address large unmet medical needs.
Glactone Pharma AB is a privately held Swedish biotech company founded in 2012 by the innovator group and the Swedish life science company AQILION AB (legacy Partners for Development Investments in Life Sciences P.U.L.S. AB). On December 9, 2019, AQILION AB announced that the company is selling its entire stake in the portfolio company Glactone Pharma AB to Daniel Lifveredson Invest AB, see the press release.
Glactone Pharma is founded on research that has demonstrated that the natural product galiellalactone can inhibit the growth of prostate cancer cells. With these results as the starting point the company has focused on discovering and developing novel drug-like compounds that display efficacious and selective STAT3 inhibition in vitro and in specific immune-oncology and prostate cancer models.
The company is based on the application of long-standing research from Lund University and Skåne University Hospital in Sweden, and Cordoba University in Spain. To read more about our research, see Publications.
To initiate a project and take it all the way to a successful exit requires an organization with the right people in the right positions at the right time.
Glactone Pharma is organized to represent all the necessary skills and competences of an innovative and successful biotech company.
The company is run as a virtual organization with project management, financing, accounting and administrative support being provided by Aqilion, www.aqilion.com.
Glactone Pharma has a highly dedicated and experienced management team and board which are key to the project development. Furthermore, Glactone Pharma has active collaborations with the innovators and the scientific advisory board, providing the company with world class scientific input.
The innovators behind Glactone Pharma are Olov Sterner, Professor of Organic Chemistry at Lund University Hospital, Rebecka Hellsten and Martin Johansson from Lund University Hospital, Anders Bjartell, Professor of Urology at Skåne University Hospital in Malmö, Lund University, Lund (all in Sweden); and Eduardo Muñoz at the University of Cordoba and IMIBIC, in Spain.
In addition, Glactone Pharma makes efficient use of an established international network of CROs and consultants and has access to Aqilion’s extensive partner network.
About Aqilion ‒ the majority owner
The majority owner Partners för Utvecklingsinvesteringar inom Life Science, P.U.L.S. AB changed its name to AQILION AB in the beginning of 2019. The name change marks a new phase in the development of the company, with a new strategy and identity.
Aqilion is a Swedish life science company that focuses on pharmaceutical projects with potential to improve quality of life for patients, while generating value for health services and society.
Learn more at www.aqilion.com.